11th December 2019

Dear Healthcare Professional

XIAFLEX® (COLLAGENASE CLOSTRIDIUM HISTOLYTICUM)
PRODUCT APPROVAL LAPSE ON 31 MARCH 2020

In follow-up to our earlier communication, regarding the cessation of distribution of XIAFLEX® (collagenase clostridium histolyticum) in New Zealand, we wanted to provide you with an update on the deregistration date. This notification serves as a three month notice period of our intention to deregister the product on **31 March 2020**.

Surgical and non-surgical procedures remain viable treatment options for consideration by both healthcare professionals and patients for any conditions previously treated with XIAFLEX®.

We encourage healthcare professionals to report any suspected adverse events to the Centre for Adverse Reactions Monitoring (CARM). This can be done via the online reporting form, available at https://nzphvc.otago.ac.nz/report/ or alternatively phone 03 479 7247 or email carmnz@otago.ac.nz.

For copies of the full XIAFLEX® Datasheet please refer to the Medsafe website: www.medsafe.govt.nz.

If you have further questions regarding the deregistration of XIAFLEX®, please contact Janssen Medical Information via email (medinfo@janau.its.jnj.com) or telephone (0800 800 806).

Yours sincerely,

Kate Norton
Actelion Business Unit Head

Dr Sophie Glover-Koudounas
Executive Director, Medical & Scientific Affairs
Janssen

Actelion, a business unit of Janssen-Cilag Pty Ltd
ACN 000 129 975
1-5 Khartoum Road I Macquarie Park NSW 2113 I phone +61 2 9815 3333 or 1800 226 334 I fax +61 2 9815 3300
www.janssen.com/australia
CP-129041 Date of preparation: December 2019